These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 25933931)

  • 1. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
    Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
    Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
    Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
    Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
    Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
    Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity Assessment After Different Adjuvant Hypofractionated Radiotherapy Concurrently Associated with Trastuzumab in Early Breast Cancer.
    Bonzano E; Guenzi M; Corvò R
    In Vivo; 2018; 32(4):879-882. PubMed ID: 29936473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
    Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
    Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses.
    Bian SX; Korah MP; Whitaker TR; Ji L; Groshen S; Chung E
    Clin Breast Cancer; 2017 Nov; 17(7):510-515. PubMed ID: 28412326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
    JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
    Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
    Radiother Oncol; 2009 Jan; 90(1):122-6. PubMed ID: 18976826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy.
    Yu AF; Ho AY; Braunstein LZ; Thor ME; Lee Chuy K; Eaton A; Mara E; Cahlon O; Dang CT; Oeffinger KC; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2019 Apr; 32(4):521-528. PubMed ID: 30826225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
    Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
    Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of High-Sensitivity Cardiac Troponin I Values and Cardiac Radiation Doses in Patients with Left-Sided Breast Cancer Undergoing Hypofractionated Adjuvant Radiotherapy with Concurrent Anti-HER2 Therapy.
    Antunac K; Mayer L; Banovic M; Beketic-Oreskovic L
    Curr Oncol; 2023 Oct; 30(10):9049-9062. PubMed ID: 37887554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
    Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
    J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
    Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
    Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
    Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
    J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
    Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.